NLRP3/IL-1 and MyD-88/CCL2 pathway were reduced by inclisiran under exposure to anthracyclines and HER-2 blocking agent
29 August 2025 (07:00 - 18:00)
Organised by: 
About the speaker
National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
8 More presentations in this session
Doctor T. Goncalves (Toronto, CA)
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Doctor T. Goncalves (Toronto, CA)
Professor T. Marwick (Melbourne, AU)
Doctor J. Wong (Melbourne, AU)
Access the full session
The Event
ESC Congress 2025
29 August - 1 September 2025
